Predictions
Hive Digital Technologies Ltd.
Start price
Target price
Perf. (%)
€4.10
19.09.22
19.09.22
-
19.09.23
19.09.23
-38.54%
08.11.22
08.11.22
Could be worthwhile Investment >10% per year
Significant cyclical dependencies
Riot Blockchain Inc.
Start price
Target price
Perf. (%)
€6.20
19.09.22
19.09.22
-
19.09.23
19.09.23
-18.43%
08.11.22
08.11.22
Could be worthwhile Investment >10% per year
Very high cyclical dependencies
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€1.65
18.09.22
18.09.22
-
18.09.23
18.09.23
-3.77%
01.10.22
01.10.22
Risky Investment
Alumil S.A.
Start price
Target price
Perf. (%)
€1.93
17.09.22
17.09.22
€0.000
17.09.23
17.09.23
-8.90%
01.10.22
01.10.22
Revenue decline/stagnation expected
Risky balance sheet
Increased challenges to pay loans and raise capital
Below average Management
Palatin Technologies Inc.
Start price
Target price
Perf. (%)
€7.79
17.09.22
17.09.22
€3.00
17.09.23
17.09.23
-22.91%
01.10.22
01.10.22
High valuation
Bad rating
Little Investments for future growth
ROE lower than 10% per year
Sabina Gold & Silver Corp.
Start price
Target price
Perf. (%)
€0.76
17.09.22
17.09.22
€1.00
17.09.23
17.09.23
-2.01%
20.09.22
20.09.22
Top 10 in its market
Future proof or reliable business model
Could be very worthwhile Investment >20% year
Known brand
Proton Motor Power Systems plc
Start price
Target price
Perf. (%)
€0.13
15.09.22
15.09.22
-
15.09.23
15.09.23
-22.46%
16.09.23
16.09.23
Could be worthwhile Investment >10% per year
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€1.62
14.09.22
14.09.22
-
14.09.23
14.09.23
1.70%
17.09.22
17.09.22
Risky Investment
Proton Motor Power Systems plc
Start price
Target price
Perf. (%)
€0.13
14.09.22
14.09.22
-
14.09.23
14.09.23
19.88%
30.11.22
30.11.22
Toughbuilt Industries Inc.
Start price
Target price
Perf. (%)
€2.77
13.09.22
13.09.22
€1.00
13.09.23
13.09.23
-19.91%
17.09.22
17.09.22
Could be worthwhile Investment >10% per year
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€2.62
13.09.22
13.09.22
-
13.09.23
13.09.23
-37.10%
17.09.22
17.09.22
Could be very worthwhile Investment >20% year
Leap Therapeutics Inc.
Start price
Target price
Perf. (%)
€12.96
13.09.22
13.09.22
-
13.09.23
13.09.23
-17.60%
18.09.22
18.09.22
Could be worthwhile Investment >10% per year
NeXR Technologies SE
Start price
Target price
Perf. (%)
€1.00
08.09.22
08.09.22
€0.000
08.09.23
08.09.23
-96.59%
09.09.23
09.09.23
Business model of the past or high risk
Little known brand
Significant cyclical dependencies
Below average Marketposition
Ahlers AG ST
Start price
Target price
Perf. (%)
€1.09
08.09.22
08.09.22
€0.000
08.09.23
08.09.23
-18.35%
17.09.22
17.09.22
Probably not worthwhile Investment
Bad culture
Below average Management
Celldex Therapeutics
Start price
Target price
Perf. (%)
€29.80
07.09.22
07.09.22
€50.00
31.12.25
31.12.25
15.44%
19.07.24
19.07.24
Could be very worthwhile Investment >20% year
Bitcoin Group SE
Start price
Target price
Perf. (%)
€20.66
07.09.22
07.09.22
€19.00
07.09.23
07.09.23
-2.23%
03.10.22
03.10.22
Very low/no dividend yield expected
Bad rating
Risky balance sheet
ROE lower than 5% per year
Vizsla Silver Corp.
Start price
Target price
Perf. (%)
€1.28
06.09.22
06.09.22
€2.00
06.09.23
06.09.23
-25.39%
07.09.23
07.09.23
Could be very worthwhile Investment >20% year
Palatin Technologies Inc.
Start price
Target price
Perf. (%)
€4.55
06.09.22
06.09.22
-
06.09.23
06.09.23
-53.45%
06.09.23
06.09.23
ETFS Commodity Securities Ltd
Start price
Target price
Perf. (%)
-
06.09.22
06.09.22
-
06.09.23
06.09.23
0.00%
06.09.23
06.09.23
ETFS Commodity Securities Ltd
Start price
Target price
Perf. (%)
-
06.09.22
06.09.22
-
06.09.23
06.09.23
0.00%
06.09.23
06.09.23
ETFS Commodity Securities Ltd
Start price
Target price
Perf. (%)
-
06.09.22
06.09.22
-
06.09.23
06.09.23
0.00%
06.09.23
06.09.23
Rock Tech Lithium Inc.
Start price
Target price
Perf. (%)
€2.62
05.09.22
05.09.22
€4.00
05.09.23
05.09.23
-6.88%
17.09.22
17.09.22
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group